Management of patients with hepatitis B in special populations

World Journal of Gastroenterology

Volumn 21, Issue 6, 2015, Pages 1738-1748

  Cholongitas, Evangelos ^a   Tziomalos, Konstantinos ^b   Pipili, Chrysoula ^c  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c Laiki Merimna ^*  (Greece)

Author keywords

Antiviral therapy; Entecavir; Hepatitis B; Telbivudine; Tenofovir

Indexed keywords

ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; TELBIVUDINE; TENOFOVIR; VIRUS DNA; HEPATITIS B HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CHEMOTHERAPY; CHILDHOOD DISEASE; CHRONIC HEPATITIS; CHRONIC KIDNEY DISEASE; DRUG CHOICE; DRUG INDICATION; GRAFT RECIPIENT; HEALTH CARE QUALITY; HEMODIALYSIS PATIENT; HEPATITIS B; HIGH RISK PATIENT; HIGH RISK PREGNANCY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; PERINATAL PERIOD; PREGNANCY; PREGNANT WOMAN; RECURRENT INFECTION; THIRD TRIMESTER PREGNANCY; TREATMENT WITHDRAWAL; VIRUS LOAD; VIRUS TRANSMISSION; VULNERABLE POPULATION; ADVERSE EFFECTS; AGE; COMORBIDITY; DRUG EFFECTS; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; IMMUNOCOMPROMISED PATIENT; MALE; PATHOGENICITY; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

AGE FACTORS; ANTIVIRAL AGENTS; COMORBIDITY; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULINS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; PATIENT SELECTION; PREGNANCY; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84922747904     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i6.1738     Document Type: Article

References (89)

1. Maddrey WC. Hepatitis B: an important public health issue. J Med Virol 2000; 61: 362-366 [PMID: 10861647 DOI: 10.1002/1096-9071(200007)61:3<362]
2. Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol 2012; 57: 442-450 [PMID: 22504333 DOI: 10.1016/j.jhep.2012.02.033]
3. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185 [PMID: 22436845]
4. Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002; 97 : 2886-2895 [PMID: 12425564 DOI: 10.1111/j.1572-0241.2002.07057.x]
5. Calvaruso V, Craxì A. Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible? Liver Int 2014; 34 Suppl 1: 85-90 [PMID: 24373083 DOI: 10.1111/liv.12395]
6. Coffin CS, Fung SK, Ma MM. Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines. Can J Gastroenterol 2012; 26: 917-938 [PMID: 23248795]
7. Murray KF, Carithers RL. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology 2005; 41: 1407-1432 [PMID: 15880505 DOI: 10.1002/hep.20704]
8. Cholongitas E, Germani G, Burroughs AK. Prioritization for liver transplantation. Nat Rev Gastroenterol Hepatol 2010; 7: 659-668 [PMID: 21045793 DOI: 10.1038/nrgastro.2010.169]
9. Degertekin B, Han SH, Keeffe EB, Schiff ER, Luketic VA, Brown RS, Emre S, Soldevila-Pico C, Reddy KR, Ishitani MB, Tran TT, Pruett TL, Lok AS. Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am J Transplant 2010; 10: 1823-1833 [PMID: 20346062 DOI: 10.1111/j.1600-6143.2010.03046.x]
10. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662 [PMID: 19714720 DOI: 10.1002/hep.23190]
11. Papatheodoridis GV, Cholongitas E, Archimandritis AJ, Burroughs AK. Current management of hepatitis B virus infection before and after liver transplantation. Liver Int 2009; 29: 1294-1305 [PMID: 19619264 DOI: 10.1111/j.1478-3231.2009.02085.x]
12. Fabrizi F, Martin P, Dixit V, Kanwal F, Dulai G. HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 2005; 5: 2913-2921 [PMID: 16303005 DOI: 10.1111/j.1600-6143.2005.01113.x]
13. Papatheodoridis GV, Sevastianos V, Burroughs AK. Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. Am J Transplant 2003; 3: 250-258 [PMID: 12614278 DOI: 10.1034/j.1600-6143.2003.00063.x]
14. Picciotto FP, Tritto G, Lanza AG, Addario L, De Luca M, Di Costanzo GG, Lampasi F, Tartaglione MT, Marsilia GM, Calise F, Cuomo O, Ascione A. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007; 46: 459-465 [PMID: 17196700 DOI: 10.1016/j.jhep.2006.10.017]
15. Roche B, Samuel D. Hepatitis C virus treatment pre- and post-liver transplantation. Liver Int 2012; 32 Suppl 1: 120-128 [PMID: 22212582 DOI: 10.1111/j.1478-3231.2011.02714.x]
16. Roche B, Sebagh M, Canfora ML, Antonini T, Roque-Afonso AM, Delvart V, Saliba F, Duclos-Vallee JC, Castaing D, Samuel D. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl 2008; 14: 1766-1777 [PMID: 19025933 DOI: 10.1002/lt.21635]
17. Fontana RJ, Hann HW, Perrillo RP, Vierling JM, Wright T, Rakela J, Anschuetz G, Davis R, Gardner SD, Brown NA. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002; 123 : 719-727 [PMID: 12198698 DOI: 10.1053/gast.2002.35352]
18. Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, Tillmann H, Samuel D, Zeuzem S, Villeneuve JP, Arterburn S, Borroto-Esoda K, Brosgart C, Chuck S. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudineresistant hepatitis B: final long-term results. Liver Transpl 2007; 13: 349-360 [PMID: 17326221 DOI: 10.1002/lt.20981]
19. Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, Suh DJ. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010; 52 : 176-182 [PMID: 20006394 DOI: 10.1016/j.jhep.2009.11.007]
20. Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suet-Hing Wong F, Chang TT, Horban A, Wang C, Kwan P, Buti M, Prieto M, Berg T, Kitrinos K, Peschell K, Mondou E, Frederick D, Rousseau F, Schiff ER. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011; 53 : 62-72 [PMID: 21254162 DOI: 10.1002/hep.23952]
21. Chan HL, Chen YC, Gane EJ, Sarin SK, Suh DJ, Piratvisuth T, Prabhakar B, Hwang SG, Choudhuri G, Safadi R, Tanwandee T, Chutaputti A, Yurdaydin C, Bao W, Avila C, Trylesinski A. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis. J Viral Hepat 2012; 19: 732-743 [PMID: 22967105 DOI: 10.1111/j.1365-2893.2012.01600.x]
22. Hyun JJ, Seo YS, Yoon E, Kim TH, Kim DJ, Kang HS, Jung ES, Kim JH, An H, Kim JH, Yim HJ, Yeon JE, Lee HS, Byun KS, Um SH, Kim CD, Ryu HS. Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis. Liver Int 2012; 32: 656-664 [PMID: 22099071 DOI: 10.1111/j.1478-3231.2011.02676.x]
23. Cholongitas E, Papatheodoridis GV, Goulis I, Vlachogiannakos J. The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis. Annals of Gastroenterol 2014; In press
24. Wang JY. Antiviral therapy for hepatitis B virus-related decompensated cirrhosis. J Dig Dis 2012; 13: 555-557 [PMID: 23107441 DOI: 10.1111/j.1751-2980.2012.00630.x]
25. Ye XG, Su QM. Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: meta-analysis. World J Gastroenterol 2013; 19: 6665-6678 [PMID: 24151397 DOI: 10.3748/wjg.v19.i39.6665]
26. Chen CH, Lin CL, Hu TH, Hung CH, Tseng PL, Wang JH, Chang JY, Lu SN, Chien RN, Lee CM. Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation. J Hepatol 2014; 60: 1127-1134 [PMID: 24583247 DOI: 10.1016/j.jhep.2014.02.013]
27. Wong VW, Chan FK. Regression of cirrhosis with long-term tenofovir treatment. Gastroenterology 2013; 145: 481-482 [PMID: 23791793 DOI: 10.1053/j.gastro.2013.06.019]
28. Singal AK, Fontana RJ. Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis. Aliment Pharmacol Ther 2012; 35 : 674-689 [PMID: 22257108 DOI: 10.1111/j.1365-2036.2011.04990.x]
29. Gane EJ, Deray G, Liaw YF, Lim SG, Lai CL, Rasenack J, Wang Y, Papatheodoridis G, Di Bisceglie A, Buti M, Samuel D, Uddin A, Bosset S, Trylesinski A. Telbivudine improves renal function in patients with chronic hepatitis B. Gastroenterology 2014; 146: 138-146.e5 [PMID: 24067879 DOI: 10.1053/j.gastro.2013.09.031]
30. Lee M, Oh S, Lee HJ, Yeum TS, Lee JH, Yu SJ, Kim HY, Yoon JH, Lee HS, Kim YJ. Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovirbased combination therapy. J Viral Hepat 2014; 21: 873-881 [PMID: 24351112 DOI: 10.1111/jvh.12217]
31. Han Z, Shi Y, Zhu J, Chen Y, Yin F, Xia L, Luo G, Gao Z, Liu J, Jia G, Li C, Zhou X, Han Y. Forty-eight-week retrospective study of telbivudine and lamivudine treatment in patients with hepatitis B-related cirrhosis. J Viral Hepat 2013; 20 Suppl 1: 58-64 [PMID: 23458526 DOI: 10.1111/jvh.12065]
32. Huang Y, Wu H, Wu S, Fu D, Ma Y, Shen X. A meta-analysis of nucleos(t)ide analogues in patients with decompensated cirrhosis due to hepatitis B. Dig Dis Sci 2013; 58: 815-823 [PMID: 23053891 DOI: 10.1007/s10620-012-2414-y]
33. Ramachandran P, Fraser A, Agarwal K, Austin A, Brown A, Foster GR, Fox R, Hayes PC, Leen C, Mills PR, Mutimer DJ, Ryder SD, Dillon JF. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Aliment Pharmacol Ther 2012; 35: 647-662 [PMID: 22296568 DOI: 10.1111/j.1365-2036.2012.04992.x]
34. Cholongitas E, Goulis J, Akriviadis E, Papatheodoridis GV. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review. Liver Transpl 2011; 17 : 1176-1190 [PMID: 21656655 DOI: 10.1002/lt.22354]
35. Cholongitas E, Papatheodoridis GV. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review. Am J Transplant 2013; 13 : 353-362 [PMID: 23137006 DOI: 10.1111/j.1600-6143.2012.04315.x]
36. Cholongitas E, Goulis I, Antoniadis N, Fouzas I, Imvrios G, Papanikolaou V, Akriviadis E. New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence. Transpl Int 2014; 27: 1022-1028 [PMID: 24909714 DOI: 10.1111/tri.12370]
37. Wesdorp DJ, Knoester M, Braat AE, Coenraad MJ, Vossen AC, Claas EC, van Hoek B. Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective. J Clin Virol 2013; 58: 67-73 [PMID: 23880162 DOI: 10.1016/j.jcv.2013.06.035]
38. Fung J, Chan SC, Cheung C, Yuen MF, Chok KS, Sharr W, Chan AC, Cheung TT, Seto WK, Fan ST, Lai CL, Lo CM. Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. Am J Gastroenterol 2013; 108: 942-948 [PMID: 23629601 DOI: 10.1038/ajg.2013.111]
39. Laryea MA, Watt KD. Immunoprophylaxis against and prevention of recurrent viral hepatitis after liver transplantation. Liver Transpl 2012; 18: 514-523 [PMID: 22315212 DOI: 10.1002/lt.23408]
40. Tahara H, Tanaka Y, Ishiyama K, Ide K, Shishida M, Irei T, Ushitora Y, Ohira M, Banshodani M, Tashiro H, Itamoto T, Asahara T, Imamura M, Takahashi S, Chayama K, Ohdan H. Successful hepatitis B vaccination in liver transplant recipients with donor-specific hyporesponsiveness. Transpl Int 2009; 22: 805-813 [PMID: 19490542 DOI: 10.1111/j.1432-2277.2009.00864.x]
41. Chaib E, Coimbra BG, Galvão FH, Tatebe ER, Shinzato MS, D' Albuquerque LA, Massad E. Does anti-hepatitis B virus vaccine make any difference in long-term number of liver transplantation? Clin Transplant 2012; 26 : E590-E595 [PMID: 23083337 DOI: 10.1111/ctr.12030]
42. Cholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol 2010; 52 : 272-279 [PMID: 20034693 DOI: 10.1016/j.jhep.2009.11.009]
43. Cholongitas E, Vasiliadis T, Antoniadis N, Goulis I, Papanikolaou V, Akriviadis E. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation. Transpl Infect Dis 2012; 14 : 479-487 [PMID: 22624695 DOI: 10.1111/j.1399-3062.2012.00741.x]
44. Pipili CL, Papatheodoridis GV, Cholongitas EC. Treatment of hepatitis B in patients with chronic kidney disease. Kidney Int 2013; 84: 880-885 [PMID: 23783238 DOI: 10.1038/ki.2013.249]
45. Bhimma R, Coovadia HM. Hepatitis B virus-associated nephropathy. Am J Nephrol 2004; 24: 198-211 [PMID: 14988643 DOI: 10.1159/000077065]
46. Guillevin L, Mahr A, Callard P, Godmer P, Pagnoux C, Leray E, Cohen P; French Vasculitis Study Group. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 2005; 84 : 313-322 [PMID: 16148731 DOI: 10.1097/01.md.0000180792.80212.5e]
47. Wang NS, Wu ZL, Zhang YE, Guo MY, Liao LT. Role of hepatitis B virus infection in pathogenesis of IgA nephropathy. World J Gastroenterol 2003; 9: 2004-2008 [PMID: 12970894]
48. Yi Z, Jie YW, Nan Z. The efficacy of anti-viral therapy on hepatitis B virus-associated glomerulonephritis: A systematic review and meta-analysis. Ann Hepatol 2011; 10: 165-173 [PMID: 21502678]
49. Xirouchakis E, Marelli L, Cholongitas E, Manousou P, Calvaruso V, Pleguezuelo M, Guerrini GP, Maimone S, Kerry A, Hajjawi M, Nair D, Thomas M, Patch D, Burroughs AK. Comparison of cystatin C and creatinine-based glomerular filtration rate formulas with 51Cr-EDTA clearance in patients with cirrhosis. Clin J Am Soc Nephrol 2011; 6 : 84-92 [PMID: 20829419 DOI: 10.2215/CJN.03400410]
50. Lledó JL, Fernández C, Gutiérrez ML, Ocaña S. Management of occult hepatitis B virus infection: an update for the clinician. World J Gastroenterol 2011; 17 : 1563-1568 [PMID: 21472122 DOI: 10.3748/wjg.v17.i12.1563]
51. Keyvani H, Agah S, Kabir A, Alavian SM. Prevalence and risk factors of isolated anti-HBc antibody and occult hepatitis B infection in hemodialysis patients: a nationwide study. Ann Hepatol 2013; 12: 213-219 [PMID: 23396732]
52. Soni R, Horowitz B, Unruh M. Immunization in end-stage renal disease: opportunity to improve outcomes. Semin Dial 2013; 26: 416-426 [PMID: 23751048 DOI: 10.1111/sdi.12101]
53. Fabrizi F, Messa P, Dixit V, Martin P. Therapy with nucleos(t)ide analogues: current role in dialysis patients. Int J Artif Organs 2010; 33: 329-338 [PMID: 20669138]
54. Tseng GY, Lin HJ, Fang CT, Cheng YT, Huang CH, Tseng GC, Wang PC, Hung TL, Deng YC, Tsai CC, Yang KY. Hemodialysis reduces the viral load in uremic patients with chronic hepatitis B infection. Ren Fail 2008; 30: 1000-1005 [PMID: 19016152 DOI: 10.1080/08860220802406377]
55. Burroughs AK, Cholongitas E. Non-invasive tests for liver fibrosis: encouraging or discouraging results? J Hepatol 2007; 46: 751-755 [PMID: 17383047 DOI: 10.1016/j.jhep.2007.02.017]
56. Pipili C, Cholongitas E. Management of patients with hepatitis B and C before and after liver and kidney transplantation. World J Hepatol 2014; 6: 315-325 [PMID: 24868325 DOI: 10.4254/wjh.v6.i5.315]
57. Fabrizi F, Dixit V, Martin P. Meta-analysis: anti-viral therapy of hepatitis B virus-associated glomerulonephritis. Aliment Pharmacol Ther 2006; 24 : 781-788 [PMID: 16918881 DOI: 10.1111/j.1365-2036.2006.03041.x]
58. Pipili C, Cholongitas E, Papatheodoridis G. Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease. Aliment Pharmacol Ther 2014; 39: 35-46 [PMID: 24299322 DOI: 10.1111/apt.12538]
59. Papatheodoridis GV . Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues? Liver Int 2013; 33 Suppl 1: 151-156 [PMID: 23286859 DOI: 10.1111/liv.12054]
60. Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis 2011; 57: 773-780 [PMID: 21435764 DOI: 10.1053/j.ajkd.2011.01.022]
61. Lu K, Wang HP, Chen YS. Outcomes of kidney transplantation recipients with hepatitis in the antiviral therapy era: a single-center experience. Transplant Proc 2014; 46: 460-463 [PMID: 24655988 DOI: 10.1016/j.transproceed.2013.11.041]
62. Pham PT, Pham PA, Pham PC, Parikh S, Danovitch G. Evaluation of adult kidney transplant candidates. Semin Dial 2010; 23: 595-605 [PMID: 21175834 DOI: 10.1111/j.1525-139X.2010.00809.x]
63. Chopra A, Cantarovich M, Bain VG. Simultaneous liver and kidney transplants: optimizing use of this double resource. Transplantation 2011; 91: 1305-1309 [PMID: 21512431 DOI: 10.1097/TP.0b013e31821bad1b]
64. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 Suppl 3: S1-155 [PMID: 19845597]
65. Cosconea S, Fontaine H, Méritet JF, Corouge M, Sogni P, Vallet-Pichard A, Mallet V, Legendre C, Pol S. Benefits associated with antiviral treatment in kidney allograft recipients with chronic hepatitis B virus infection. J Hepatol 2012; 57: 55-60 [PMID: 22414762 DOI: 10.1016/j.jhep.2012.02.020]
66. Yap DY, Tang CS, Yung S, Choy BY, Yuen MF, Chan TM. Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments. Transplantation 2010; 90: 325-330 [PMID: 20562676 DOI: 10.1097/TP.0b013e3181e5b811]
67. Cho JH, Lim JH, Park GY, Kim JS, Kang YJ, Kwon O, Choi JY, Park SH, Kim YL, Kim HK, Huh S, Kim CD. Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection. Transpl Infect Dis 2014; 16: 295-303 [PMID: 24628837 DOI: 10.1111/tid.12202]
68. Jonas MM, Block JM, Haber BA, Karpen SJ, London WT, Murray KF, Narkewicz MR, Rosenthal P, Schwarz KB, McMahon BJ. Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options. Hepatology 2010; 52: 2192-2205 [PMID: 20890947 DOI: 10.1002/hep.23934]
69. Haber BA, Block JM, Jonas MM, Karpen SJ, London WT, McMahon BJ, Murray KF, Narkewicz MR, Rosenthal P, Schwarz KB. Recommendations for screening, monitoring, and referral of pediatric chronic hepatitis B. Pediatrics 2009; 124: e1007-e1013 [PMID: 19805457 DOI: 10.1542/peds.2009-0567]
70. Barbera C, Bortolotti F, Crivellaro C, Coscia A, Zancan L, Cadrobbi P, Nebbia G, Pillan MN, Lepore L, Parrella T. Recombinant interferon-alpha 2a hastens the rate of HBeAg clearance in children with chronic hepatitis B. Hepatology 1994; 20: 287-290 [PMID: 8045488 DOI: 10.1002/hep.1840200203]
71. Sokal EM, Conjeevaram HS, Roberts EA, Alvarez F, Bern EM, Goyens P, Rosenthal P, Lachaux A, Shelton M, Sarles J, Hoofnagle J. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 1998; 114: 988-995 [PMID: 9558288 DOI: 10.1016/S0016-5085(98)70318-X]
72. Bortolotti F, Jara P, Barbera C, Gregorio GV, Vegnente A, Zancan L, Hierro L, Crivellaro C, Vergani GM, Iorio R, Pace M, Con P, Gatta A. Long term effect of alpha interferon in children with chronic hepatitis B. Gut 2000; 46 : 715-718 [PMID: 10764718 DOI: 10.1136/gut.46.5.715]
73. Jonas MM, Mizerski J, Badia IB, Areias JA, Schwarz KB, Little NR, Greensmith MJ, Gardner SD, Bell MS, Sokal EM. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002; 346: 1706-1713 [PMID: 12037150 DOI: 10.1056/NEJMoa012452]
74. Murray KF, Szenborn L, Wysocki J, Rossi S, Corsa AC, Dinh P, McHutchison J, Pang PS, Luminos LM, Pawlowska M, Mizerski J. Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B. Hepatology 2012; 56: 2018-2026 [PMID: 22544804 DOI: 10.1002/hep.25818]
75. Sokal EM, Paganelli M, Wirth S, Socha P, Vajro P, Lacaille F, Kelly D, Mieli-Vergani G. Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. J Hepatol 2013; 59: 814-829 [PMID: 23707367 DOI: 10.1016/j.jhep.2013.05.016]
76. Huang QT, Wei SS, Zhong M, Hang LL, Xu YY, Cai GX, Liu Q, Yu YH. Chronic hepatitis B infection and risk of preterm labor: a meta-analysis of observational studies. J Clin Virol 2014; 61: 3-8 [PMID: 24973811 DOI: 10.1016/j.jcv.2014.06.006]
77. ter Borg MJ, Leemans WF, de Man RA, Janssen HL. Exacerbation of chronic hepatitis B infection after delivery. J Viral Hepat 2008; 15: 37-41 [PMID: 18088243]
78. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ 2006; 332 : 328-336 [PMID: 16443611 DOI: 10.1136/bmj.38719.435833.7C]
79. McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP, Maynard JE. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985; 151: 599-603 [PMID: 3973412 DOI: 10.1093/infdis/151.4.599]
80. Tassopoulos NC, Papaevangelou GJ, Sjogren MH, Roumeliotou-Karayannis A, Gerin JL, Purcell RH. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology 1987; 92: 1844-1850 [PMID: 3569758]
81. Han GR, Cao MK, Zhao W, Jiang HX, Wang CM, Bai SF, Yue X, Wang GJ, Tang X, Fang ZX. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 2011; 55: 1215-1221 [PMID: 21703206 DOI: 10.1016/j.jhep.2011.02.032]
82. Wiseman E, Fraser MA, Holden S, Glass A, Kidson BL, Heron LG, Maley MW, Ayres A, Locarnini SA, Levy MT. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust 2009; 190: 489-492 [PMID: 19413519]
83. Han L, Zhang HW, Xie JX, Zhang Q, Wang HY, Cao GW. A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus. World J Gastroenterol 2011; 17: 4321-4333 [PMID: 22090789 DOI: 10.3748/wjg.v17.i38.4321]
84. Brown RS, Verna EC, Pereira MR, Tilson HH, Aguilar C, Leu CS, Buti M, Fagan EA. Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry. J Hepatol 2012; 57: 953-959 [PMID: 22766470 DOI: 10.1016/j.jhep.2012.06.031]
85. Roche B, Samuel D. The difficulties of managing severe hepatitis B virus reactivation. Liver Int 2011; 31 Suppl 1: 104-110 [PMID: 21205146 DOI: 10.1111/j.1478-3231.2010.02396.x]
86. Shouval D, Shibolet O. Immunosuppression and HBV reactivation. Semin Liver Dis 2013; 33 : 167-177 [PMID: 23749673 DOI: 10.1055/s-0033-1345722]
87. Mindikoglu AL, Regev A, Schiff ER. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol 2006; 4: 1076-1081 [PMID: 16861051 DOI: 10.1016/j.cgh.2006.05.027]
88. Cholongitas E, Papatheodoridis GV. Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation. World J Gastroenterol 2013; 19: 9189-9197 [PMID: 24409047 DOI: 10.3748/wjg.v19.i48.9189]
89. Cholongitas E, Vasiliadis T, Goulis I, Fouzas I, Antoniadis N, Papanikolaou V, Akriviadis E. Telbivudine is associated with improvement of renal function in patients transplanted for HBV liver disease. J Viral Hepat 2014; Epub ahead of print [PMID: 25385239 DOI: 10.1111/jvh.12362]